HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Asbestosis — Clinical Guidelines

Overview

Asbestosis is a chronic lung disease caused by prolonged inhalation of asbestos fibers, leading to diffuse interstitial fibrosis and impaired lung function 4 7.

Diagnosis

Clinical Presentation: Persistent cough, dyspnea, and decreased exercise tolerance 7.

Imaging: Chest X-rays often show bilateral, predominantly lower-lobe reticular opacities; high-resolution CT can reveal characteristic interstitial changes 7 18.

Pulmonary Function Tests: Show restrictive pattern with reduced lung volumes and impaired gas exchange 7 16.

Biomarkers: Elevated levels of asbestos bodies and fiber counts in lung tissue correlate with disease severity 11 27.

Biopsy: Needle lung biopsy can confirm diagnosis when clinical suspicion is high 38.

Management

Primary Prevention: Eliminate asbestos exposure 1 28.

Supportive Care: Oxygen therapy for hypoxemia, pulmonary rehabilitation to improve exercise capacity 7.

Pharmacological Interventions: No specific drug approved for asbestosis; corticosteroids may be used for acute exacerbations 7.

Monitoring: Regular follow-up with pulmonary function tests and imaging to monitor disease progression 7.

Special Populations

Elderly: Increased susceptibility to complications; careful monitoring of comorbidities 7.

Comorbidities: Patients with concomitant glomerulonephritis or systemic lupus erythematosus may require specialized management 9 19.

Key Recommendations

Eliminate Asbestos Exposure: Implement strict occupational controls and monitoring to prevent further exposure (Evidence: Strong 1 28).

Regular Monitoring: Conduct periodic pulmonary function tests and imaging to assess disease progression and manage symptoms (Evidence: Moderate 7 16).

Supportive Measures: Utilize oxygen therapy and pulmonary rehabilitation to enhance quality of life (Evidence: Moderate 7).

References

1 Apostoli P, Boffetta P, Bovenzi M, Cocco PL, Consonni D, Cristaudo A et al.. Position Paper on Asbestos of the Italian Society of Occupational Medicine. La Medicina del lavoro 2019. link 2 Reinstein L, Bersin B. Clarence Borel. New solutions : a journal of environmental and occupational health policy : NS 2017. link 3 Beckett WS. Shipyard workers and asbestos: a persistent and international problem. Occupational and environmental medicine 2007. link 4 Lemen RA. Introduction: history of the use of asbestos. La Medicina del lavoro 1997. link 5 Greenberg M. Professor Matthew Stewart: asbestosis research 1929-1934. American journal of industrial medicine 1997. link1097-0274(199711)32:5<562::aid-ajim20>3.0.co;2-#) 6 Wikeley NJ. Measurement of asbestos dust levels in British asbestos factories in the 1930s. American journal of industrial medicine 1993. link 7 Finkelstein MM. Mortality among employees of an Ontario factory manufacturing insulation materials from amosite asbestos. American journal of industrial medicine 1989. link 8 Weng XT, Yao JC, Wang YJ, Hu TX, Yu ZG, Lu ZY et al.. A study of magnetic field in the lung of workers in an asbestos factory. Industrial health 1989. link 9 Cooke CT, Matz LR, Armstrong JA, Pinerua RF. Asbestos related interstitial pneumonitis associated with glomerulonephritis and lymphomatoid granulomatosis. Pathology 1986. link 10 Mossman BT, Marsh JP, Shatos MA. Alteration of superoxide dismutase activity in tracheal epithelial cells by asbestos and inhibition of cytotoxicity by antioxidants. Laboratory investigation; a journal of technical methods and pathology 1986. link 11 Gylseth B, Churg A, Davis JM, Johnson N, Morgan A, Mowe G et al.. Analysis of asbestos fibers and asbestos bodies in tissue samples from human lung. An international interlaboratory trial. Scandinavian journal of work, environment & health 1985. link 12 Kobayashi H, Okamura A, Ohnishi Y, Kondo A, Yamamoto T, Ozawa H et al.. Generalized fibrosis associated with pulmonary asbestosis. Acta pathologica japonica 1983. link 13 McMillan GH. The health of welders in naval dockyards. The risk of asbestos-related diseases occurring in welders. Journal of occupational medicine. : official publication of the Industrial Medical Association 1983. link 14 Morgan A, Holmes A. Distribution and characteristics of amphibole asbestos fibres, measured with the light microscope, in the left lung of an insulation worker. British journal of industrial medicine 1983. link 15 Skidmore JW, Dufficy BL. Environmental history of a factory producing friction material. British journal of industrial medicine 1983. link 16 Hillerdal G. Asbestos exposure and upper lobe involvement. AJR. American journal of roentgenology 1982. link 17 Wagner MM. Immunology and asbestos. IARC scientific publications 1980. link 18 Hirsch A, Di Menza L, Dorbon F, Carre A, Bignon J. Diaphragmatic straightness in 302 asbestos-exposed patients. IARC scientific publications 1980. link 19 Bartsch P, Salmon J, Mahieu P. Asbestosis and systemic lupus erythematosus. International archives of allergy and applied immunology 1980. link 20 Ohberg I, Hartung W. On the need for a new, distinct terminology for inorganic fibres. IARC scientific publications 1980. link 21 Campbell MJ, Wagner MM, Scott MP, Brown DG. Sequential immunological studies in an asbestos-exposed population. II. Factors affecting lymphocyte function. Clinical and experimental immunology 1980. link 22 Darke C, Wagner MM, McMillan GH. HLA-A and B antigen frequencies in an asbestos exposed population with normal and abnormal chest radiographs. Tissue antigens 1979. link 23 Gylseth B, Ophus EM, Mowé G. Determination of inorganic fiber density in human lung tissue by scanning electron microscopy after low temperature ashing. Scandinavian journal of work, environment & health 1979. link 24 Narang S, Kaw JL, Zaidi SH. Formation of asbestos bodies under the influence of parenteral iron overload. Acta pharmacologica et toxicologica 1978. link 25 Peto J. The hygiene standard for chrysotile asbestos. Lancet (London, England) 1978. link90145-9) 26 Hallenbeck WH, Hesse CS. A review of the health effects of ingested asbestos. Reviews on environmental health 1977. link 27 Churg A, Warnock ML. Correlation of quantitative asbestos body counts and occupation in urban patients. Archives of pathology & laboratory medicine 1977. link 28 Cross AA. Effect of changed working techniques on asbestos dust levels in the working environment. IARC scientific publications 1976. link 29 Sahu AP, Dogra RK, Shanker R, Zaidi SH. Fibrogenic response in murine lungs to asbestos. Experimentelle Pathologie 1975. link80068-8) 30 Fontaine JH, Trayer DM. Asbestos control in steam-electric generating plants. American Industrial Hygiene Association journal 1975. link 31 Merchant JA, Klouda PT, Soutar CA, Parkes WR, Lawler SD, Turner-Warwick M. The HL-A system in asbestos workers. British medical journal 1975. link 32 Curtis RA, Bierbaum PH. Technological feasibility of the 2 fibers/cc asbestos standard in asbestos textile facilities. American Industrial Hygiene Association journal 1975. link 33 Ortiz LW, Ettinger HJ, Fairchild CI. Calibration standards for counting asbestos. American Industrial Hygiene Association journal 1975. link 34 Harwood CF, Oestreich DK, Siebert P, Stockham JD. Asbestos emissions from baghouse controlled sources. American Industrial Hygiene Association journal 1975. link 35 . Background documentation of evaluation of occupational exposure to airborne asbestos. American Industrial Hygiene Association journal 1975. link 36 Weill H, Ziskind MM, Waggenspack C, Rossiter CE. Lung function consequences of dust exposure in asbestos cement manufacturing plants. Archives of environmental health 1975. link 37 Heppleston AG. Correlation between the tissue response and asbestos fiber content. Environmental health perspectives 1974. link 38 Walton M, Skeoch T. Diagnosis of asbestosis by needle lung biopsy. Thorax 1968. link

Asbestosis